Delayed Onset of Thrombotic Microangiopathy from Carfilzomib in Multiple Myeloma
Author Information
Author(s): Ceglédi Andrea, Király Ágnes, Várkonyi Andrea, Tasnády Szabolcs, Andrikovics Hajnalka, Fekete Mónika, Szabó Bálint G., Szemlaky Zsuzsanna, Szilágyi Ágnes, Sinkovits György, Prohászka Zoltán, Réti Marienn, Mikala Gábor
Primary Institution: Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary
Hypothesis
Can carfilzomib therapy lead to delayed onset thrombotic microangiopathy (TMA) in multiple myeloma patients?
Conclusion
Ongoing monitoring for TMA during carfilzomib therapy is crucial, as early diagnosis and intervention can lead to complete remission.
Supporting Evidence
- The patient developed TMA symptoms 11 months after starting carfilzomib therapy.
- Immediate discontinuation of carfilzomib and initiation of plasmapheresis led to complete remission of TMA symptoms.
- Laboratory findings confirmed the diagnosis of TMA with schistocytosis and complement activation.
Takeaway
This study talks about a woman who got very sick from a medicine called carfilzomib almost a year after starting it, showing that doctors need to keep checking for problems even after a long time.
Methodology
A retrospective analysis of medical records was conducted for a patient diagnosed with IgA kappa myeloma who developed TMA after 11 months of carfilzomib therapy.
Limitations
The findings may not be widely generalizable as this is a single case study.
Participant Demographics
A 47-year-old Caucasian woman.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website